Berinert (C1 Esterase Inhibitor) prior authorization for Hereditary Angioedema
Customize your policy alerts
Sign up for AvMed Policy Pub. 100-2 alerts
Get alerted when Policy Pub. 100-2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization and step-edit requirements for Berinert (J0597) for treatment of acute attacks and prophylaxis of hereditary angioedema (HAE) for AvMed members; applies to prescribers and administrators requesting coverage.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.